FIRST WAVE BIOPHARMA (FWBI) Stock Price & Overview
NASDAQ:FWBI • US33749P4081
Current stock price
The current stock price of FWBI is 2.96 USD. Today FWBI is up by 4.59%. In the past month the price increased by 4.23%. In the past year, price decreased by -93.21%.
FWBI Key Statistics
- Market Cap
- 4.621M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -88.75
- Dividend Yield
- N/A
FWBI Stock Performance
FWBI Stock Chart
FWBI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FWBI. When comparing the yearly performance of all stocks, FWBI is a bad performer in the overall market: 98.3% of all stocks are doing better.
FWBI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to FWBI. FWBI has a bad profitability rating. Also its financial health evaluation is rather negative.
FWBI Earnings
FWBI Forecast & Estimates
8 analysts have analysed FWBI and the average price target is 36.72 USD. This implies a price increase of 1140.54% is expected in the next year compared to the current price of 2.96.
FWBI Groups
Sector & Classification
FWBI Financial Highlights
Over the last trailing twelve months FWBI reported a non-GAAP Earnings per Share(EPS) of -88.75. The EPS increased by 75.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233.87% | ||
| ROE | -446.8% | ||
| Debt/Equity | 0.17 |
FWBI Ownership
FWBI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FWBI
Company Profile
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
Company Info
IPO: 2016-10-11
FIRST WAVE BIOPHARMA
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
CEO: James Sapirstein
Employees: 10
Phone: 15615897020
FIRST WAVE BIOPHARMA / FWBI FAQ
What does FIRST WAVE BIOPHARMA do?
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
Can you provide the latest stock price for FIRST WAVE BIOPHARMA?
The current stock price of FWBI is 2.96 USD. The price increased by 4.59% in the last trading session.
Does FIRST WAVE BIOPHARMA pay dividends?
FWBI does not pay a dividend.
How is the ChartMill rating for FIRST WAVE BIOPHARMA?
FWBI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the employee count for FWBI stock?
FIRST WAVE BIOPHARMA (FWBI) currently has 10 employees.
Can you provide the market cap for FIRST WAVE BIOPHARMA?
FIRST WAVE BIOPHARMA (FWBI) has a market capitalization of 4.62M USD. This makes FWBI a Nano Cap stock.
Can you provide the upcoming earnings date for FIRST WAVE BIOPHARMA?
FIRST WAVE BIOPHARMA (FWBI) will report earnings on 2024-08-14, before the market open.